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Telecardiology may help confront the growing burden
of monitoring the reliability of implantable defibrilla-
tors/pacemakers. Herein, we suggest that the evolv-
ing capabilities of implanted devices to monitor
patients’ status (heart rhythm, fluid overload, right
ventricular pressure, oximetry, etc.) may imply a shift
from strictly device-centered follow-up to perspectives
centered on the patient (and patient-device interac-
tions). Such approaches could provide improvements
in health care delivery and clinical outcomes, espe-
cially in the field of heart failure. Major professional,
policy, and ethical issues will have to be overcome to
enable real-world implementation. This challenge
may be relevant for the evolution of our health care
systems.
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INTRODUCTION
Long-distance transmission of data recorded by implanted
electrical devices is fast becoming a technological reality. After
initially being adopted for efficient remote follow-up of
implanted devices and patient–device interactions, use of this
technology could be extended to monitor patients’ hemody-
namic conditions. Such a shift would enable remote moni-
toring (telemonitoring) of the clinical condition of heart
failure (HF) patients and pave the way to a broad, multidis-
ciplinary approach to disease management offering potential
advantages both in terms of clinical outcome and economic
savings.
In this article, we will first consider the potential of
telemonitoring for follow-up of patients carrying implantable
devices in the context of increased usage and widening
indications. We will then look at experiences regarding the
use of external stand-alone devices to monitor HF patients.
This will lead us to consider possible additional benefits of
telemonitoring in HF patients who have indications for an
implantable cardioverter-defibrillator (ICD) or pacemaker. We
conclude by highlighting some important issues regarding this
upcoming challenge.
TECHNOLOGICAL EVOLUTION OF ELECTRICAL
DEVICES: PREMISES FOR TELEMONITORING
The use of implantable electrical devices entails periodic device
follow-up to check if the pacemaker system (device/leads) is
working properly, and to allow detection of lead failure or pulse
generator exhaustion/malfunction. Proposals to develop
transtelephonic monitoring systems as a way of reducing
cardiac pacemaker follow-up visits were first made in the
1970s.
1 The question of how best to manage the follow-up of
patients implanted with a device has become increasingly topical
in recent decades, which have also seen vast changes in cardiac
device therapy, leading to a greatly expanded population of
implantedpatientsandnewtechnicalfollow-uprequirements.
2–4
Along with new pacing functions, novel types of devices (not
primarily intended for treatment of bradycardia) have been
introduced for the treatment of HF and prevention of sudden
death.
5,6 These developments, combined with the increased
life expectancy of patients carrying pacemakers to treat
bradycardia,
7 have enlarged and diversified the population of
device recipients. A key factor in the growing device follow-up
burden has been the shift in indications for implantable
cardioverter defibrillator (ICD) from secondary to primary
prevention of sudden death.
2,8 Furthermore, indications to
device implantation have been extended to selected groups of
HF patients who may benefit from biventricular pacing
(cardiac resynchronization therapy; CRT).
6 Currently, over
225,000 pacemakers and 150,000 ICDs appear to be
implanted in the USA each year.
9 Most implanted patients
have impaired systolic left ventricular function and are
therefore at risk of events such as new-onset (or worsening)
HF, life-threatening ventricular tachyarrhythmias, atrial fibril-
lation (AF), and stroke.
The changing profile of the overall device-carrying popula-
tion (larger, more heterogeneous, and affected by more com-
plex disease) is being met by expanded device capabilities. A
single device can deliver multiple therapies, while also moni-
toring various cardiovascular parameters. Information can be
obtained on underlying heart rhythm, burden of supraventric-
ular or ventricular arrhythmias, and (in some devices) fluid
overload.
10,11 Such advances are likely to provide the premise
for relevant changes in follow-up modalities and objectives, as
discussed in the rest of this article.
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FOLLOW-UP
ICD manufacturers have developed a variety of telemonitoring
systems. Three separate systems from Medtronic, St. Jude
Medical, and Boston Scientific all currently require patients to
perform a device questioning procedure to allow data trans-
mittal to the referral center via the internet or phone network.
4
A different approach used by Biotronik (Berlin, Germany)
involves automatic transmittal (usually daily, or on appear-
ance of relevant events) from the device to a service center that
processes the data and informs physicians via the internet (or
in cases of alerts, through additional channels such as fax and
mobile phone messages).
12 Current systems for remote ICD
follow-up provide information on device status, detected events
(including intracardiac electrograms of arrhythmic events),
and the therapies delivered.
4,12–15
Although still in an experimental phase, telemonitoring can
provide a similar quality of data retrieval to conventional office
visits,
4,13,14 satisfying both clinicians
13 and patients.
13,15
Various clinically relevant points can be identified allowing
prompt intervention based on detection of abnormalities in
sensing/pacing function, evidence of new AF or of therapy
appropriately delivered for a ventricular tachyarrhythmia, and
so-called “phantom shocks” (sensations of device-delivered
shocks in the absence of detected events).
13,15
Telemonitoring of ICDs has the potential to improve
patients’ safety regarding both spontaneous clinical events
and device-related events. The device-driven aspect is of
particular interest given the problem of device advisories,
which seem to have increased in recent years.
16 The availabil-
ity of “patient alert” features in some current ICDs can
facilitate early detection of serious (sometimes life-threatening)
device system complications entailing the need for reprogram-
ming or device/lead replacement.
17
The economic potential of telemonitoring was highlighted in
a French survey, which indicated that this approach could
help cut overall ICD follow-up costs, thanks to transport
savings, particularly for patients living over 100 km from their
referring center.
18 When the costs of home monitoring were
factored in, the time to onset of cost saving ranged from about
1.5 years (for patients living >150 km from the referring center)
to about 4 years.
18 Telemonitoring may cover a wide range of
situations (including routine follow-up and nonscheduled
follow-up because of new or phantom shocks, suspected
electromagnetic interference, or suspected onset of new
arrhythmias such as AF), thereby sparing patients the need
to travel to the referring center except for reprogramming.
TELECARDIOLOGY IN THE MANAGEMENT OF HF:
EXPERIENCES WITH EXTERNAL DEVICES
There is growing interest in home-based care for HF patients to
reduce hospital admissions. Telecardiology could be a key
player in this strategy. HF is a common disease, whose
prevalence is increasing alongside the aging of the general
population. The impact of HF on health care costs is mainly
caused by hospitalization (in western countries, HF is the most
common cardiovascular cause of hospitalization in the elderly,
and repeated admissions are often required).
19 The conven-
tional approach to home monitoring relies on external devices
connected to a telecommunication system.
19 Regular (daily or
even continuous) transmittal of data regarding heart rate,
blood pressure, ECG, weight, body temperature, oxygen
saturation, or transthoracic impedance (for control of fluid
overload) can provide a basis for disease management deci-
sions. Non-randomized clinical trials on strict telemonitoring
of HF patients have identified several predictors of mortality or
hospitalization, and indicate that telemonitoring is associated
with a reduction in the number of hospitalizations in compar-
ison with regular conventional follow-up.
19,20
In a randomized controlled study of NYHA III–IV HF
patients,
21 telemonitoring of weight and symptoms led to
improved survival in the absence of reduced hospitalization
(the primary outcome measure). The Trans-European Network
Home-Care Management System (TEN-HMS) study random-
ized patients with left ventricular dysfunction and a recent
history of hospitalization because of HF either to home
telemonitoring (of weight, blood pressure, and heart rate/
rhythm, as recorded by automated external devices), to nurse
support by telephone, or to usual care. During an 8-month
follow-up, both telemonitoring and telephone support reduced
mortality in comparison with usual care. Furthermore, tele-
monitoring was associated with shorter hospital stays (but not
lower hospital admission rates).
22 So far, the benefits of
telemonitoring seem to be less impressive than was originally
hoped. Despite some cost-effectiveness evaluations,
19,20 the
overall economic profile of telemedicine awaits clarification.
23
Whereas telemonitoring has traditionally made use of
external devices, the frequent indications for electrical device
(pacemaker, ICD, or CRT) implantation in the field of HF
suggest the prospect of closer and more detailed monitoring
of patients’ conditions.
20 This avenue could become even more
attractive if the sensors integrated into implanted devices to
monitor hemodynamic conditions are further developed and
improved.
11,24,25 Although further technological evolution is
probably necessary before we can gain a true picture of the
potential of telemonitoring, even now it does seem to hold out
the prospect of improvements in the quality of life, health
status, and safety in specific groups of patients, while at the
same time enhancing economic efficiency.
MONITORING OF PATIENTS CARRYING IMPLANTED
ELECTRICAL DEVICES: A CHANGING SCENARIO
At present, HF appears to be an ideal target for pilot disease
management programs based on telemonitoring via implant-
able electrical devices. Telemonitoring of implanted devices
could provide various kinds of useful information (Table 1),
suggesting the possibility of an acceptable and efficient
strategy to improve patients’ outcomes while cutting costs.
Clinical management could greatly benefit from timely infor-
mation on electrophysiological and hemodynamic parameters
(ventricular tachyarrhythmia burden, new onset of AF, rhythm
pattern during syncope, evolution of hemodynamic state, fluid
overload, etc.).
In patients with advanced HF (NYHA class III–IV ), intratho-
racic impedance monitored by implanted devices has been
found to correlate inversely with pulmonary capillary wedge
pressure and fluid balance, and can provide early warning
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onset of symptoms).
11 This example illustrates how a device-
assisted approach could be applied in clinical practice. The
clinical potential and possible cost-effectiveness benefits
(through reductions in hospitalization- and disease-related
costs) are under evaluation.
11
The increasing capabilities of implanted devices to monitor
patients’ status suggest a shift in post-implant follow-up
objectives from a strictly device-centered perspective (“Is the
device working properly?”) to perspectives centered on the
patient–device interactions and on patient status (“Is the device
programming appropriate for the patient’s status?”“ Has some-
thing changed in the patient’s status?”“ What clinical options
are most appropriate for this patient?”). Health care could
benefit from automatic or periodic data transmission, coupled
with alert features (when the device detects significant abnor-
malities) to warn patients to contact physicians.
4,12,20 Upfront
increases in costs (physician/nurse surveillance, phone calls,
internet/phone checks, etc.) could eventually be offset by
reduced hospitalization costs, thanks to the beneficial effects
of timely recognition of changes in patients’ status and prompt
therapeutic response.
Another innovative technological approach to HF manage-
ment involves use of stand-alone devices designed exclusively
for the telemonitoring of cardiac function by measurement of
various indicators.
25 Obviously, such an approach could also
be used for patients without pacemaker or ICD indications.
However, the need for an invasive intervention entails risk–
benefit considerations (implantation side effects versus possi-
ble management benefits) that could make this approach less
amenable to study than approaches involving provision of
additional telemonitoring capabilities to routinely implanted
devices. In any case, experiences garnered in the telemonitor-
ing of pacemakers, ICDs, and CRT devices could be useful for
development and application of other implantable monitoring
systems.
TELECARDIOLOGY WITH IMPLANTED ELECTRICAL
DEVICES: PERSPECTIVES AND OPEN ISSUES
In HF, acute exacerbation is thought to contribute to disease
progression, leading to progressive ventricular dysfunction
and dilation.
26 This concept could stimulate early detection of
hemodynamic alterations as a marker of HF exacerbation.
Telemonitoring of implantable devices could enable timely
therapeutic adjustments aimed at preventing severe derange-
ment and disease progression. Such strategies might lead to
profound changes in care delivery to HF patients based on
coordinated multidisciplinary disease management with the
potential to improve outcomes.
27 Patients would be the focus
of a network of physicians and other clinicians, including the
referral electrophysiologist, HF specialist, family doctor, inter-
nists, and other relevant health professionals. Similar scenar-
ios might also be considered for diabetes and other chronic
diseases, as and when appropriate technologies become
available.
28,29
For such possibilities to become a reality, several issues
must be overcome. Technological compatibility would be an
important premise. The different proprietary technologies for
telemonitoring could pose a major obstacle to data integra-
tion.
4,13,14 Although commercial enterprises find it difficult to
agree on shared standards, within the health sector ethical
pressures might be decisive. Propagation of the Digital Imaging
and Communications in Medicine (DICOM) standard provides
a promising example.
30 Another issue regards the choice of
approach for a specific telemedicine program.
31 For example,
interactive real-time telemedicine has greater overheads than
“store-and-forward” approaches (e-mails, pre-recorded images/
videos, etc.), but permits interaction and provides more
immediate results.
29 However, the store-and-forward approach
may be fully sufficient for the purposes of telemonitoring of
patients with implantable devices, where data collection has
already been performed by the device itself.
Although development of dedicated guidelines
32 could con-
stitute a key step to improve the consistency and efficiency of
telemedicine, this topic remains largely unaddressed. Barriers
to guideline development include emphasis on technology
rather than the principles and targets of telemedicine,
33
coupled with medical organizations’ tendency to feel they lack
necessary technical expertise.
Telemedicine is particularly vulnerable to ethical and legal
conflict, mainly because the law-making process tends to lag
behind the high pace of technological evolution, and also
because of national/federal differences.
34,35 New sets of med-
icolegal regulations will be required to define professional
responsibilities for decisions guided by transmitted data,
especially with regard to suspected equipment malfunction.
Table 1. Types of Information that Implanted Devices
(Pacemakers, ICDs, Devices for CRT) with Telemonitoring
Capabilities could Potentially Provide
Information Details
Device information Battery status and voltage
P and R wave amplitudes
Capture thresholds
Lead impedance
Autocapture thresholds
Shock impedance
I n f o r m a t i o no np a t i e n t s ’ heart
rhythm/arrhythmias and on
device therapies
Heart rate
Heart rate variability
Atrial and ventricular
electrograms
Percentage atrial pacing
Percentage ventricular pacing
Number of supraventricular
tachyarrythmias (AT, AF)
Number of ventricular
tachyarrythmias (VT, VF)
Number of non-sustained VTs
Number and outcome of delivered
therapies (atrial, ventricular)
Number of aborted therapies
(atrial, ventricular)
Electrograms of detected
arrhythmias (atrial, ventricular)
Information on patients’ status
and hemodynamic condition
Right ventricular dP/dt
Right ventricular pressure
Right ventricular impedance
Venous oxygen saturation
Fluid overload
Muscular activity
Ventilation
AF atrial fibrillation, ATatrial tachycardia, CRTcardiac resynchronization
therapy, ICD implantable cardioverter-defibrillator, VF ventricular fibril-
lation, VT ventricular tachycardia.
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including emergencies.
4 Personnel accreditation/certification,
jurisdiction, and choice of law in the case of cross-border
patient–doctor relationships may be complicated (what to do
when doctors certified for given countries are contacted by
internet by patients from elsewhere?).
Widespread implementation of telemedicine will entail man-
agement of huge amounts of data, with important privacy
implications. It will be essential to define responsibilities for
data management/access (by hospital personnel, providers,
public/private institutions, etc.), and formulate regulations to
protect the rights of both patients and health care profes-
sionals. Patients’ provision of consent to medical treatment
could be a particularly delicate ethical issue. Questions
regarding protection of intellectual property rights will also
have to be addressed. From a societal perspective, implemen-
tation of telecardiology using implanted devices will obviously
depend on evidence that this option improves efficiency and is
cost effective. Moreover, research will presumably be needed to
identify subgroups of patients for whom use of specific
telemonitoring devices is both feasible and cost-effective.
CONCLUSIONS
In the context of the rapid ongoing evolution of electronic
technology, telemedicine has the potential to enhance and
rationalize clinical monitoring of patients implanted with
pacemakers, ICDs, and CRT devices. It is likely that this
prospect will be encouraged by further technological advances
in the development of useful novel sensors. A consequent shift
from device-centered to patient-oriented telemonitoring could
in turn favor a transition to a broader multidisciplinary
approach to “disease management” based on a system of
coordinated heath care interventions, not only in the field of
cardiovascular medicine. However, a series of economic,
regulatory, and organizational issues will have to be faced
before such an approach can take root in real-world clinical
practice, where institutional, cultural, and financial forces
interact in complex ways. The ability to overcome these
obstacles so as to take full advantage of the potential benefits
offered by telemedicine technology may be relevant for the
evolution of our financially challenged heath care systems.
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